Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Great Basin Scientific receives delisting warning from Nasdaq

Published 07 September 2016

Great Basin Scientific, a molecular diagnostics company, announced that it received a delisting warning from Nasdaq after 30 consecutive days of its common stock trading below the $1 minimum bid price, making it non-compliant with Nasdaq Listing Rule 5550(a)(2).

The Company will have until February 27, 2017 to regain compliance by maintaining a minimum bid price of $1 for a minimum 10 consecutive days at any time within the next 180 days.

Great Basin Scientific has already taken definitive steps to comply with the Listing Rule, in that it is seeking shareholder approval for a reverse stock split during the Annual Meeting of Stockholders being held Monday, September 12, 2016.

While Company management is confident it can meet Nasdaq compliance and continue trading its common stock on the Nasdaq Capital Market, there can be no assurances that it will be able to do so.

Additional information regarding the Company's reverse stock split is available in the definitive proxy statement filed by the Company with the U.S. Securities and Exchange Commission on August 22, 2016.

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.

 The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases.

The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.



Source: Company Press Release